曲美他嗪在缺血性心肌病心力衰竭治疗中临床效果观察

Observation of clinical effect by trimetazidine in the treatment of ischemic cardiomyopathy and heart failure

目的分析曲美他嗪在缺血性心肌病心力衰竭治疗中的临床效果。方法 90例缺血性心肌病心力衰竭患者,随机分为常规组及试验组,各45例。常规组采用常规疗法,试验组在常规组基础上给予曲美他嗪治疗。比较两组患者缺血性心肌病心力衰竭改善情况、不良反应发生情况及治疗前后患者左心室射血分数。结果试验组患者缺血性心肌病心力衰竭改善总有效率为95.56%,高于常规组的82.22%,差异具有统计学意义(P<0.05)。治疗前,常规组左心室射血分数为(38.51±0.82)%,试验组左心室射血分数为(38.34±0.81)%。治疗后,常规组左心室射血分数为(42.18±0.85)%,试验组左心室射血分数为(48.67±1.81)%。治疗前两组左心室射血分数比较,差异无统计学意义(P>0.05);治疗后均高于本组治疗前,且试验组高于常规组,差异均具有统计学意义(P<0.05)。常规组不良反应发生率为6.67%,试验组为4.44%,比较差异无统计学意义(P>0.05)。结论曲美他嗪在缺血性心肌病心力衰竭治疗中临床效果确切,可有效改善患者心功能,改善心力衰竭症状,无明显不良反应,值得推广。

Objective To analyze clinical effect by trimetazidine in the treatment of ischemiccardiomyopathy and heart failure.Methods A total of90patients with ischemic cardiomyopathy and heartfailure were randomly divided into conventional group and experimental group,with45cases in each group.Theconventional group received conventional therapy,and the experimental group received additional trimetazidineto conventional therapy.Comparison was made on improvement of ischemic cardiomyopathy and heart failure,occurrence of adverse reactions,and left ventricular ejection fraction before and after treatment betweenthe two groups.Results The experimental group the higher total effective rate in ischemic cardiomyopathyand heart failure improvement as95.56%than82.22%in the conventional group,and their difference hadstatistical significance(P<0.05).Before treatment,the conventional group had left ventricular ejection fractionas(38.51±0.82)%,and the experimental group had left ventricular ejection fraction as(38.34±0.81)%.Aftertreatment,the conventional group had left ventricular ejection fraction as(42.18±0.85)%,and the experimentalgroup had left ventricular ejection fraction as(48.67±1.81)%.The difference of left ventricular ejection fractionbefore treatment had no statistical significance between the two groups(P>0.05).Both groups had higher leftventricular ejection fraction after treatment than that before treatment,and the experimental group had higher leftventricular ejection fraction than the conventional group.Their differences all had statistical significance(P<0.05).The conventional group had incidence of adverse reactions as6.67%,which was4.44%in the experimental group,and their difference had no statistical significance(P>0.05).Conclusion Trimetazidine shows precise effect in treating ischemic cardiomyopathy and heart failure.It can effectively improve cardiac function and heart failuresymptom in patients,along with no obvious adverse reactions.This method is worth promoting.